Geron Corporation GERN
Nov 4, 2026, 11:07 AM EST
- YTD
- -26.67%
- 1 year
- -15.83%
- Market cap
- 617.93M
- Revenue (ttm)
- 204.56M
- Profit margin
- -33.05%
- EPS (ttm)
- -0.11
- Shares out
- 642.47M
- Forward P/E
- 39.25
- YTD return
- -26.67%
- 1-year return
- -15.83%
- Volume
- 5.74M
- Avg volume
- 12.08M
- Open
- 1.00
- Previous close
- 0.93
- Day's range
- 0.9614 – 1.05
- 52-week range
- 0.84 – 2.01
- Beta
- 0.60
- Price target
- 4.25 (+339.1%)
- Earnings date
- Nov 4, 2026
15m -0.0233 (-2.35%)
Key statistics
- Enterprise value
- 829.98M
- PEG ratio
- 0.00
- Price / sales
- 4.93
- Price / book
- 4.62
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 17.20%
- Free cash flow
- -78.37M
- Total cash
- 300.85M
- Total debt
- 122.14M
- Return on equity
- -28.28%
- Short % of float
- 12.56%
- 50-day average
- 1.47
- 200-day average
- 1.44
Analyst view
- Target (low)
- 3.00
- Target (mean)
- 4.25
- Target (high)
- 6.00
- Strong buy1
- Buy3
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -0.01.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -0.01 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | -0.00888 | -0.02 | -0.01 | -125.23% |
| May 6, 2026 | Mar 31, 2026 | -0.03 | -0.01 | +0.02 | +66.67% |
| Feb 25, 2026 | Dec 31, 2025 | -0.03 | -0.03 | 0.00 | 0.00% |
| Nov 5, 2025 | Sep 30, 2025 | -0.03667 | -0.03 | +0.01 | +18.19% |
| Aug 6, 2025 | Jun 30, 2025 | -0.03 | -0.02 | +0.01 | +33.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2025 | Needham | main | Buy | Buy |
| May 8, 2025 | Scotiabank | down | Sector Outperform | Sector Perform |
| Mar 12, 2025 | Needham | reit | Buy | Buy |
| Mar 12, 2025 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Feb 27, 2025 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Feb 27, 2025 | Stifel | main | Buy | Buy |
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- geron.com
News
Geron To Present Six Abstracts At 68th American Society Of Hematology Annual Meeting 
Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026 
Geron Q3 2026 Earnings Call Transcript 
Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights 
Geron Corporation to Participate in the Stifel 2026 Healthcare Conference 
Geron: Opportunity Builds Even As Struggles Continue 
Geron (GERN) Expected to Announce Earnings on Wednesday 
Wedbush Maintains Outperform on Geron, Lowers Price Target to $5 
Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth 
Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth
Your note
Sign in to keep a note on GERN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| LAWLIS VIRGIL BRYAN JR. | Director | Purchase | May 8, 2025 | 13,300 |
| ROBERTSON MICHELLE | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 17, 2026 | 17,645 |
| SAMUELS SCOTT ALAN | Officer | Purchase | Feb 26, 2025 | 26,682 |
| SCARLETT JOHN A | Chief Executive Officer | Purchase | Feb 26, 2025 | 137,500 |
| SPIEGEL ROBERT J | Director | Stock Award(Grant) | Jun 29, 2026 | 205,810 |
| ZIEGLER JAMES | Officer | Purchase | Feb 26, 2025 | 100,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.64% | 49,115,571 | 77.11M | Jun 29, 2026 |
| Soleus Capital Management, L.P. | 6.66% | 42,808,659 | 67.21M | Jun 29, 2026 |
| RA Capital Management, L.P. | 6.66% | 42,809,751 | 67.21M | Jun 29, 2026 |
| State Street Corporation | 5.58% | 35,856,671 | 56.29M | Jun 29, 2026 |
| Citadel Advisors Llc | 4.52% | 29,038,928 | 45.59M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.24% | 27,250,215 | 42.78M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.40% | 21,816,987 | 34.25M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.18% | 20,449,234 | 32.11M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.25% | 14,478,730 | 22.73M | Jun 29, 2026 |
| Vanguard Explorer Fund | 1.58% | 10,174,592 | 15.97M | Apr 29, 2026 |
| Legg Mason Partners Investment Trust-ClearBridge Small Cap Growth Fund | 0.98% | 6,316,110 | 9.92M | Apr 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.95% | 6,108,370 | 9.59M | Jun 29, 2026 |